Lower extremity arterial thromboembolisms occurring less frequently, but we are not doing much better in terms of outcomes Key findings: We analyzed 8474 patients who were hospitalized in 140 facilities for lower extremity thromboembolism (LE-TE). The age-adjusted incidence of LE-TE per 100,000 patients decreased approximately by one-half from 2003 (8.0) to 2014 (3.5) . During the same time, the likelihood of receiving antiplatelet or anticoagulant therapy increased 2.3% per year and the use of statins increased from 54% to 71%. Although the likelihood of undergoing endovascular revascularization increased 4.0% per year during this period (from 20% to 40%), clinical outcomes remained constant over time: the 1-year incidence of major limb events was 25%, major cardiac events 18%, and mortality16%.
Conclusion: The incidence of LE-TE is decreasing with increasing use of antiplatelet and anticoagulant therapies, but without change in amputation or death within 1 year of the event.
Commentary: I have not come across many recent large studies reporting LE-TE. The 30-day mortality and amputation rates in this series were about 5% and 8%, respectively, which suggests we should tell patients and their families they have more than a 10% chance of dying or losing their leg when they come to the emergency room with an acutely ischemic leg owing to thromboembolism. The study suggests that increasing use of antiplatelet agents, anticoagulants, and statins played a role in the temporal decline of LE-TE. Decreasing use of tobacco may also have played a role. However, the 1-year incidence of major limb events, cardiac events, and mortality did not change after the sentinel event.
Take-home Message: The study suggests that antiplatelet agents, anticoagulants, and statins decreased the likelihood of LE-TE over the last several years. However, if patients suffer this complication, these medications and the increased use of endovascular intervention did not improve 1-year amputation or mortality rates.
Warning to vascular surgeons who perform procedures in "out-patient" nonhospital-based facilities Study design: Opinion article. Key findings: The two largest U.S. dialysis companies, DaVita and Fresenius Medical Care, control 70% of the U.S. dialysis market and each reported an annual net income of $1 billion. Joint ventures between nephrologists and dialysis companies may lead to financial incentives for participating nephrologists, which may inappropriately influence decisions about patient care. A "striking lack of transparency" regarding joint venture arrangements currently exists. Patients cannot find out whether nephrologists referring them to a dialysis facility have financial incentives to do so.
